Janux Therapeutics, Inc. Common Stock

JANXNASDAQ • USD
10.92 USD
↘ 0.45 (3.96%)AT CLOSE (03:59 PM EST)
10.97
↗ 0.05 (0.45%)
POST MARKET (AS OF 07:35 PM EST)
Post Market
AS OF 07:35 PM EST
10.97
↗ 0.05 (0.45%)
🔴Market: CLOSED

Shares of Janux Therapeutics, Inc. Common Stock (JANX) are trading at $10.92. Technicals currently rate "Strong Sell" while our fundamental analysis reads "Neutral". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bullish Golden Cross on the moving averages. JANX is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Nov 16, 2026.

Open?$11.28
High?$11.32
Low?$10.73
Prev. Close?$11.37
Volume?788.7K
Avg. Volume?998.5K
VWAP?$10.94
Rel. Volume?0.79x
Bid / Ask
Bid?$10.80 × 1.0K
Ask?$11.12 × 200
Spread?$0.32
Midpoint?$10.96
Valuation & Ratios
Market Cap?668.1M
Shares Out?61.2M
Float?45.0M
Float %?73.6%
P/E Ratio?N/A
P/B Ratio?0.73
EPS?-$1.63
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Employees
114
Market Cap
695.7M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2021-06-11
Address
10955 VISTA SORRENTO PARKWAY
SAN DIEGO, CA 92130
Phone: (858) 751-4493
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
99
Momentum?
77
Short Sent.?
54
Piotroski F-Score?2/9Weak
Altman Z-Score?5.63Safe
Confidence?51%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?11.84%High
Short Interest?5.3M
Days to Cover?8.0
Free Float45.0M
Avg Daily Volume667.6K
Settlement Date2026-10-30
Financial Health
Current Ratio?17.69Strong
Quick Ratio?17.69Strong
Cash Ratio?0.77Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.73CHEAP▾
P/S?
Peers
100
S&P
3
28.69HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-4.6CHEAP▾
EV/Sales?
Peers
100
S&P
3
26.89HIGH▾
Returns & Efficiency
ROE?
S&P
9
-11.0%WEAK▾
ROA?
S&P
3
-10.2%WEAK▾
Cash Flow & Enterprise
FCF?$-54160000
Enterprise Value?$626.3M
Fundamentals ratios updated end of day